Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye (NCT01692964), a registered phase not stated study. The primary outcome is Negative and Positive Agreement of the InflammaDry at Diagnosis of Dry Eyes.

2. Clinical Question

The central statistical question is how often the device’s classifications agreed with the clinical assessment used as the reference. Agreement is not the same as comparing outcomes between randomized treatment groups: the record describes a diagnostic evaluation and does not state that allocation was randomized. The registry does not report the observed agreement percentages or their confidence intervals, so the magnitude and precision of agreement cannot be judged from the listed outcome definition alone.

3. Trial Design

The record describes a completed clinical evaluation of InflammaDry for detecting dry eye. Rapid Pathogen Screening is listed as the sponsor. The study start is recorded as 2012-10, primary completion as 2013-05, and enrollment as 237. InflammaDry is the listed device intervention, and the arm description says patients suspected of having dry eye would be tested with it.

The design information does not describe a randomized comparison or a separate control arm. The registry’s design note specifically cautions that allocation is not stated and that the arms are not a like-for-like control comparison. The relevant comparison in the primary outcome is instead between the device result and clinical assessment. The listed clinical assessment includes tear break-up time, Schirmer tear testing, and corneal staining. The outcome description also refers to assessment with and without OSDI as a confirmatory test.

The primary outcome is titled negative and positive agreement of InflammaDry at diagnosis of dry eyes. It is expressed as a percentage of cases, with a 95% confidence interval, and a timeframe of 20 minutes. The registry lists one outcome measure and 0 analyses. It does not report the achieved agreement estimates, the analysis population, or details of how discordant results were handled.

The record identifies the study as completed, but completion status alone does not establish that all planned measurements were available or analyzed. Details such as participant flow, eligibility criteria, recruitment setting, the clinical assessment procedure, and the protocol’s statistical plan are not reported in the registry record. The design should therefore be read as a registry-described diagnostic evaluation, not as a treatment-effect trial with a randomized comparator.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Negative and Positive Agreement of the InflammaDry at Diagnosis of Dry Eyes, measured over 20 minutes.

The primary endpoint concerns negative and positive agreement between InflammaDry and clinical assessment for diagnosis of dry eyes. The registry defines negative agreement as the percentage of true negative cases compared with clinical assessment, corresponding to specificity. It defines positive agreement as the percentage of true positive cases compared with clinical assessment, corresponding to sensitivity. The outcome is reported as a percentage of cases, with a 95% confidence interval, over a 20-minute timeframe.

These measures are used in diagnostic evaluations because they describe how test classifications correspond to a reference assessment across negative and positive classifications. A confidence interval describes uncertainty around an estimate; a narrower interval generally indicates greater precision, while a wider interval indicates greater uncertainty. This is a general statistical explanation, not a finding about the precision of this evaluation: the registry record does not report the actual agreement estimates or confidence intervals.

The comparator is clinical assessment involving tear break-up time, Schirmer tear testing, and corneal staining, with the outcome description also considering OSDI as a confirmatory test. The record does not define a single independent reference standard or give the detailed classification rules. That matters because agreement estimates depend on how the reference assessment defines positive and negative cases. No result can be inferred from the endpoint’s name or definition alone.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does agreement measure?

In a diagnostic evaluation, agreement describes how often a test classification matches a reference classification. The registry uses positive and negative agreement and describes these in terms of sensitivity and specificity, respectively. Positive agreement concerns cases identified as positive by the clinical assessment; negative agreement concerns cases identified as negative by that assessment. These are conditional measures: their interpretation depends on how the reference assessment defines the relevant cases.

Agreement is not the same as a causal treatment effect. There is no randomized treatment contrast described in this record. The statistical task is to characterize how the device classifications correspond to the clinical assessment, rather than to estimate a difference in health outcomes between treatment groups. The record’s design note states that allocation is not stated and that arms are not a like-for-like control comparison.

Why does the reference assessment matter?

A diagnostic result can only be interpreted relative to the assessment used to classify cases. Here, the registry names tear break-up time, Schirmer tear testing, and corneal staining, and it refers to including or excluding OSDI as a confirmatory test. The record does not describe the exact rule that combines these assessments, whether one measure takes priority, or how disagreement between assessment components is resolved.

As a general statistical point, changing the reference definition can change which cases count as positive or negative, and can therefore change agreement estimates. A reference assessment is not automatically an error-free truth simply because it serves as the comparator. The registry does not report a validation procedure for the reference classification, so the relationship between the clinical assessment and an underlying disease state cannot be evaluated from this record.

How should the confidence interval be read?

The endpoint specifies a 95% confidence interval. In general, a confidence interval is a range constructed by a statistical procedure to represent uncertainty in an estimate. It helps readers assess precision alongside the point estimate: a more narrowly bounded range indicates greater precision under the method’s assumptions, while a broader range indicates less precision. The interval does not guarantee that the true value lies within the particular reported range.

No point estimate or interval is listed in the registry record. Consequently, there is no basis for evaluating precision, determining whether the interval is wide or narrow, or relating the observed estimate to a benchmark. The confidence level stated in the endpoint description is not itself an observed result.

What can the sample size tell us?

The record lists enrollment of 237, but it does not report how many participants contributed to each endpoint calculation or whether all enrolled participants had complete test and reference-assessment data. Enrollment is not automatically the denominator for every diagnostic estimate. A denominator can depend on whether participants received the test, whether the reference classification was available, and how missing or indeterminate results were handled; those details are not reported in the registry record.

Sample-size calculations, when available, describe design assumptions and planned precision or power under specified conditions. They are not observed results. This record does not report a sample-size justification, target precision, or a statistical plan that would allow the intended precision of the agreement estimates to be assessed. No sample-size adequacy conclusion can be drawn from enrollment alone.

Why can agreement depend on the study population?

As a general statistical consideration, the mix of cases in a diagnostic evaluation can affect the distribution of test results and the stability of estimated agreement. The clinical context, participant characteristics, and spectrum of findings may differ across settings. The registry identifies patients suspected of having dry eye but does not report detailed eligibility criteria or participant characteristics. Generalizability therefore cannot be assessed from the description alone.

Moreover, the stated timeframe is 20 minutes, but the record does not explain the timing procedures or whether all components of clinical assessment were performed within that window. Timing can be relevant to diagnostic comparisons when measurements are intended to be paired. This is a methodological consideration, not a claim about how the study was conducted.

What is missing from the analysis description?

The registry lists 0 analyses, and it does not report an analysis population, rules for missing observations, handling of indeterminate tests, or a statistical analysis plan. It also does not state whether confidence intervals were adjusted for any design features or how results were intended to be presented for the assessment with and without OSDI. Without these details and the estimates themselves, readers cannot independently assess the analytic choices or reproduce the reported outcome.

General statistical principles can explain why these details matter, but they cannot fill gaps in the record. The relevant interpretation remains limited to the described endpoint and comparison. No unadjusted recalculation, sponsor analysis, or sample-size planning result is reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The endpoint description refers to positive and negative agreement and to clinical assessment with and without OSDI as a confirmatory test. These are distinct aspects of the diagnostic evaluation. The registry does not describe a prespecified hierarchy among them, identify a single primary contrast within these variants, or state whether any adjustment for multiple analyses was planned. The statistical plan and multiplicity approach are not reported in the registry record.

As a general statistical point, when several outcomes or analysis variants are examined, the chance of obtaining an apparently notable result can increase if each is interpreted separately without accounting for the number of comparisons. A prespecified analysis strategy can clarify which estimate is primary and how other results should be treated. Because no analysis results are listed and the plan is not reported, the implications of multiplicity cannot be evaluated for this study.

The registry lists 0 analyses, so it does not provide analyzed outcome values or show which participants were included in any endpoint calculation. It does not report missing-data counts, exclusions, loss to follow-up, or handling of indeterminate test and reference results. These omissions do not establish that data were missing or that participants were excluded; they mean that the record does not describe these matters. The enrolled total of 237 should not be assumed to be the denominator for each agreement estimate.

The record also does not specify whether the analysis population was defined by all enrolled participants, participants with paired device and clinical-assessment results, or another rule. Such definitions can affect the interpretation of diagnostic estimates, particularly if incomplete or indeterminate results are handled differently. No conclusion about analysis-population selection, missing-data bias, or multiplicity control is possible from the registry information.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s safety listing for the InflammaDry group records 237 participants at risk, 0 serious events, and 0 other events. The deaths field is null. These entries are the safety counts recorded in the registry; a null entry is not a reported numeric count and should not be read as equivalent to a stated zero.

Counts at risk describe the group denominator associated with the listing, while event counts describe entries recorded in the corresponding categories. They do not, on their own, explain what events were collected, how events were defined, the observation period, or how completeness of reporting was assessed. Those details are not reported in the registry record. The record also lists no serious-event terms.

Zero recorded events in a category should not be interpreted as proof that no event occurred outside the recorded information or that every possible safety outcome was assessed. The safety listing does not provide a comparative risk estimate because a like-for-like control group is not described. It also does not support a broader safety conclusion beyond the recorded counts. The death field’s null value should remain distinct from the explicit 0 entries for serious and other events.

12. What the Result Does, and Does Not, Mean

The registry record describes a completed diagnostic evaluation of InflammaDry, a device intended to detect elevated MMP-9 in tear fluid. It identifies a primary question about negative and positive agreement with clinical assessment for dry eye, lists a 20-minute timeframe, and records enrollment of 237 participants. It also identifies the clinical assessments used in the comparison and mentions assessment with and without OSDI as a confirmatory test.

Those details establish what the study was intended to evaluate, but the registry does not report the actual agreement percentages or confidence intervals. The record therefore does not show how closely device classifications matched clinical assessment or how precise any estimate was. It cannot establish strong, weak, or otherwise meaningful diagnostic agreement from the outcome title or endpoint definition alone.

The clinical assessment is the stated comparator, and the record does not provide a detailed reference-classification rule. As a general matter, agreement with a clinical assessment is not automatically equivalent to agreement with an error-free measure of underlying disease. The record also does not report participant characteristics or the analysis population, limiting assessment of how the study results might apply to other populations even if estimates were available.

The safety listing records 0 serious events and 0 other events for the InflammaDry group, with a null death field. These entries describe the recorded counts only. They do not supply a comparative safety assessment or detail the completeness and duration of event monitoring.

In short, the record supports an account of the diagnostic question, the named comparison methods, and the enrolled population. It does not supply the results needed to judge diagnostic performance, statistical precision, or broader applicability. No treatment-effect conclusion is appropriate because the record describes a diagnostic evaluation rather than a randomized treatment comparison.

13. Why This Trial Matters Statistically

This evaluation raises a central issue in diagnostic statistics: performance is defined relative to a comparator. InflammaDry was evaluated against clinical assessment using tear break-up time, Schirmer tear testing, and corneal staining, with the outcome description also considering OSDI as a confirmatory test. The selected assessment and the rule used to classify cases are therefore central to interpreting any agreement estimate.

The endpoint also distinguishes negative from positive agreement. Reporting both can be informative because a diagnostic test may correspond differently with a reference assessment across positive and negative classifications. The registry’s endpoint description makes this distinction, but does not report either estimate or its confidence interval. The statistical question is clear; the numerical evidence needed to answer it is absent from the registry record.

The record illustrates why enrollment alone cannot communicate precision. Although 237 participants are listed as enrolled, the denominator contributing to each measure, the availability of paired results, and the handling of indeterminate or missing observations are not reported. A reader cannot determine the effective analysis population or assess the precision of estimates without those details and the outcome values.

It also demonstrates the importance of separating a completed study record from a complete results account. The study status is completed, but the record lists 0 analyses and no numerical diagnostic findings. Completion status does not substitute for estimates, uncertainty intervals, or a transparent analysis description. This distinction is important when registry records are used to understand what a study can and cannot establish.

Finally, the design note warns against treating the listed arms as a randomized, like-for-like comparison. For a diagnostic evaluation, the relevant comparison is the test against the clinical assessment, not a treatment contrast. Reading the design and endpoint together prevents unsupported causal interpretations and keeps attention on the missing agreement results.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report the observed positive or negative agreement values, their 95% confidence intervals, or any analysis results. It lists 0 analyses. This is the primary limitation for statistical interpretation: the planned measurement is described, but its numerical findings are unavailable in the record.

Methodological detail is sparse. The record does not give eligibility criteria beyond describing patients suspected of having dry eye, participant characteristics, recruitment setting, test procedures, or the exact clinical classification rule. Although tear break-up time, Schirmer tear testing, corneal staining, and OSDI are named, the process for combining or interpreting them is not reported. The record also does not explain how discordant or indeterminate results were classified.

The analysis population and denominator for the endpoint are not reported. Neither are missing-data counts, exclusions, or rules for incomplete device or clinical-assessment results. Enrollment of 237 therefore cannot be assumed to equal the number contributing to either agreement estimate. The statistical analysis plan, confidence-interval method, and approach to the assessment with and without OSDI are also not reported in the registry record.

The design note states that allocation is not stated and that the arms are not a like-for-like control comparison. There is no basis to interpret this as a randomized treatment comparison. The record also does not report a sample-size justification or a precision target. Finally, the safety listing lacks event definitions and monitoring details; the null death field is not a numeric zero. These limitations constrain what can be concluded from the posted record, without establishing that the unreported procedures or data were absent from the study itself.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye — NCT01692964.
• Registry record last updated 2020-10-12; status last verified 2020-09.
• Results first posted 2020-10-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed clinical evaluation of InflammaDry, a device for detecting elevated MMP-9 in tear fluid. Rapid Pathogen Screening is listed as sponsor. The study start is recorded as 2012-10, primary completion as 2013-05, and enrollment as 237.

The primary outcome is negative and positive agreement with clinical assessment for dry eye, defined as a percentage of cases with a 95% confidence interval and a 20-minute timeframe. The assessment includes tear break-up time, Schirmer tear testing, and corneal staining, with and without OSDI as a confirmatory test. The registry lists 0 analyses and does not report the outcome estimates.

The safety listing records 0 serious events and 0 other events among 237 at risk; the death field is null. The record notes that allocation is not stated and that the arms are not a like-for-like control comparison. Diagnostic performance and its precision cannot be judged from the posted results because the numerical agreement findings are not reported in the registry record.